Home > Cardiology > ESC 2020 > Late-Breaking Science > Reduced progression of coronary atherosclerosis with icosapent ethyl

Reduced progression of coronary atherosclerosis with icosapent ethyl

Presented By
Prof. Matthew Budoff, Harbor-UCLA Medical Center, USA
Conference
ESC 2020
Trial
EVAPORATE trial
The EVAPORATE trial showed that icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, significantly reduced multiple plaque components over 18 months, including a significant regression of low-attenuation plaque volume on multidetector computed tomography (MDCT) [1,2]. Although statins reduce cardiovascular (CV) events and slow progression of coronary atherosclerosis, significant CV risk remains. The REDUCE-IT trial previously showed that the addition of icosapent ethyl to statin therapy reduced initial CV events by 25% and total CV events by 32% [3]. However, the mechanisms of this benefit are not yet fully explained. The EVAPORATE trial set out to further assess the effects of icosapent ethyl plaque volume, measured by serial MDCT, compared with placebo [2]. Icosapent ethyl versus placebo The randomised, double-blind, placebo-con...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on